Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.36 |
| ▸ | RBP4 | P02753 | 3/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784480 | 0.91 | RORC (0.40) | EPHX2RORCF10CYP2C9PDK2 | |
| SCHEMBL27920394 | 0.87 | EPHX2 (0.36) | EPHX2F10TTRTLR9TLR8 | |
| SCHEMBL785538 | 0.86 | EPHX2 (0.44) | EPHX2RORCF10TTRTLR9 | |
| SCHEMBL784667 | 0.86 | KMT2A (0.40) | RORCF10TLR9TLR8TLR7 | |
| SCHEMBL784970 | 0.83 | F10 (0.39) | EPHX2RORCF10TTRTLR9 | |
| SCHEMBL784895 | 0.83 | F10 (0.43) | F10TLR9TLR8TLR7 | |
| SCHEMBL27920397 | 0.83 | TLR9 (0.36) | EPHX2F10TLR9TLR8TLR7 | |
| SCHEMBL27920388 | 0.80 | TLR9 (0.38) | EPHX2F10TTRTLR9TLR8 | |
| SCHEMBL785587 | 0.80 | RORC (0.43) | EPHX2RORCF10TLR9TLR8 | |
| SCHEMBL28802471 | 0.80 | F10 (0.41) | F10TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| CN-103097354-A | Substituted benzamide compounds | GRUENENTHAL CHEMIE | 2013-05-08 | — | — | CN | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| CN-103097354-A | Substituted benzamide compounds | GRUENENTHAL CHEMIE | 2013-05-08 | — | — | CN | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | EPHX2 1475/4885RORC 4667/4885F10 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.